Dengue
Target product profile for Dengue
Dengue
Target product profile for Dengue
Target product profile: A new dengue treatment to prevent progression from mild or moderate to severe disease
| Acceptable | Ideal | |
| Target population | Children and adults with dengue fever without warning signs | Children and adults, including infants (under 2 years old), adults over 65 years old, and people with key comorbidities |
| Geographic distribution | All regions | All regions |
| Efficacy | Reduce duration of viraemia and duration of symptoms Efficacy in all dengue virus serotypes (DENV 1-4) Efficacy in primary and secondary dengue | Prevent progression to severe dengue and Efficacy in all dengue virus serotypes (DENV 1-4) |
| Safety | Well tolerated; no need for lab monitoring | Well tolerated; no need for lab monitoring |
| Contraindications | Pregnant women Individuals with renal and hepatic impairment | No contraindications |
| Interactions | No clinically significant interactions with medicines used for key comorbidities | |
| Presentation (route | Oral tablet or dispersible oral tablet; | Oral tablet or dispersible oral tablet |
| Dosing regimen | 3 to 4 times daily Maximum To be used in the first 48-72 hours following onset of | Once daily To be used in the first 48-72 hours following onset of symptoms |
| Bioavailability | Fast-acting, high volume of distribution | Fast-acting, high volume of distribution |
| Price and cost of treatment | Affordable to governments in developing countries for large-scale use | Affordable to governments in developing countries for large-scale use |
Target Product Profile Dengue Treatment to Prevent Progression to Severe Disease
| Acceptable | Ideal | |
| Target population | Children and adults with dengue fever without warning signs | Children and adults, including infant (under 2 years old), pregnant women, adults over 65 years old and people with key comorbidities |
| Geographic Distribution | All regions | All regions |
| Efficacy | Reduce duration of viremia and duration of symptoms Efficacy to all serotypes of DENV (1-4) Efficacy in primary and secondary dengue | Prevent the evolution to severe dengue and its related complications (number and duration of hospitalisations, need for intensive care/deaths) Efficacy to all serotypes of DENV (1-4) Efficacy in primary and secondary dengue |
| Safety | Well tolerated; no need for lab monitoring | Well tolerated; no need for lab monitoring |
| Contraindications | Pregnant women Individuals with renal and hepatic impairment | No contraindication |
| Interactions | No clinically significant interaction with medicines used for key comorbidities | |
| Presentation (route of administration) | Tablet/dissolvable tablet (oral); injectable (IV single dose) | Tablet/dissolvable tablet (oral) |
| Dosing regimen | 3 to 4 times a day Maximum during 5 days To be used at the first 48-72 hours of the onset of the symptoms | Once daily To be used at the first 48-72 hours of the onset of the symptoms |
| Bioavailability | Fast-acting, high volume of distribution | Fast-acting, high volume of distribution |
| Price and cost of treatment | Affordable to be procured by governments in developing countries and used in large scale | Affordable to be procured by governments |
Making medical history for neglected patients
We develop urgently needed treatments for neglected patients and ensure they’re affordable, available, and adapted to the communities who need them
Stay connected
Get our latest news, personal stories, research articles, and job opportunities.
